This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Parola, P.
Right arrow Articles by Brouqui, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Parola, P.
Right arrow Articles by Brouqui, P.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, March 2001, p. 932-935, Vol. 45, No. 3
0066-4804/01/$04.00+0   DOI: 10.1128/AAC.45.3.932-935.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.

Controlled Trial of 3-Day Quinine-Clindamycin Treatment versus 7-Day Quinine Treatment for Adult Travelers with Uncomplicated Falciparum Malaria Imported from the Tropics

Phillippe Parola,1 Stephane Ranque,1 Sekene Badiaga,1 Mohamadou Niang,1 Olivier Blin,2 Jean-Jacques Charbit,3 Jean Delmont,1 and Philippe Brouqui1,*

Service des Maladies Tropicales et Infectieuses1 and Pharmacie Centrale,3 CHU Nord, 13015 Marseille, and CPCET, CHU Timone, 13005 Marseille,2 France

Received 13 September 2000/Returned for modification 17 October 2000/Accepted 15 November 2000

We conducted a randomized, double-blind, placebo-controlled trial to compare a 3-day quinine-clindamycin regimen (group QC) with a 7-day quinine regimen (group Q) for the treatment of uncomplicated Plasmodium falciparum malaria in travelers returning from the tropics. A total of 55 and 53 patients in groups Q and QC were analyzed, respectively. Adverse effects were similar in both groups, although two patients in group Q had severe adverse reactions, leading to the cessation of treatment. The 28-day cure rate for the evaluated patients (per-protocol analysis) was 100% for group QC, whereas it was 96.3% for group Q (P = 0.5). The 28-day cure rate in the intention-to-treat analysis was 96.2% for group QC, whereas it was 94.6% for group Q (P = 1). There were no significant differences between the two regimens with regard to parasite and fever clearance times. Our study shows that the 3-day quinine-clindamycin regimen is well tolerated and compares favorably with a 7-day quinine treatment. This short-term regimen had previously been evaluated only in areas of endemicity. According to our results, the 3-day quinine-clindamycin regimen may be an alternative for the treatment of imported uncomplicated P. falciparum malaria in travelers returning from the tropics.


* Corresponding author. Mailing address: Service des Maladies Tropicales et Infectieuses, CHU Nord, 13015 Marseille, France. Phone: (33) 4 91 96 89 36. Fax: (33) 4 91 96 89 38. E-mail: Philippe.Brouqui{at}medecine.univ-mrs.fr.


Antimicrobial Agents and Chemotherapy, March 2001, p. 932-935, Vol. 45, No. 3
0066-4804/01/$04.00+0   DOI: 10.1128/AAC.45.3.932-935.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.



This article has been cited by other articles:

  • Achan, J., Tibenderana, J. K, Kyabayinze, D., Wabwire Mangen, F., Kamya, M. R, Dorsey, G., D'Alessandro, U., Rosenthal, P. J, Talisuna, A. O (2009). Effectiveness of quinine versus artemether-lumefantrine for treating uncomplicated falciparum malaria in Ugandan children: randomised trial. BMJ 339: b2763-b2763 [Abstract] [Full Text]  
  • Parola, P., Pradines, B., Simon, F., Carlotti, M.-P., Minodier, P., Ranjeva, M.-P., Badiaga, S., Bertaux, L., Delmont, J., Morillon, M., Silai, R., Brouqui, P., Parzy, D. (2007). Antimalarial Drug Susceptibility and Point Mutations Associated with Drug Resistance in 248 Plasmodium falciparum Isolates Imported from Comoros to Marseille, France in 2004 2006. Am J Trop Med Hyg 77: 431-437 [Abstract] [Full Text]  
  • Griffith, K. S., Lewis, L. S., Mali, S., Parise, M. E. (2007). Treatment of Malaria in the United States: A Systematic Review. JAMA 297: 2264-2277 [Abstract] [Full Text]  
  • MILLER, R. S., WONGSRICHANALAI, C., BUATHONG, N., McDANIEL, P., WALSH, D. S., KNIRSCH, C., OHRT, C. (2006). EFFECTIVE TREATMENT OF UNCOMPLICATED PLASMODIUM FALCIPARUM MALARIA WITH AZITHROMYCIN-QUININE COMBINATIONS: A RANDOMIZED, DOSE-RANGING STUDY.. Am J Trop Med Hyg 74: 401-406 [Abstract] [Full Text]  
  • BROUQUI, P., ROLAIN, J. M., FOUCAULT, C., RAOULT, D. (2005). Q FEVER AND PLASMODIUM FALCIPARUM MALARIA CO-INFECTION IN A PATIENT RETURNING FROM THE COMOROS ARCHIPELAGO. Am J Trop Med Hyg 73: 1028-1030 [Abstract] [Full Text]  
  • Matteelli, A., Saleri, N., Bisoffi, Z., Gregis, G., Gaiera, G., Visona, R., Tedoldi, S., Scolari, C., Marocco, S., Gulletta, M. (2005). Mefloquine versus Quinine plus Sulphalene-Pyrimethamine (Metakelfin) for Treatment of Uncomplicated Imported Falciparum Malaria Acquired in Africa. Antimicrob. Agents Chemother. 49: 663-667 [Abstract] [Full Text]  
  • Adehossi, E., Parola, P., Foucault, C., Delmont, J., Brouqui, P., Badiaga, S., Ranque, S. (2003). Three-Day Quinine-Clindamycin Treatment of Uncomplicated Falciparum Malaria Imported from the Tropics. Antimicrob. Agents Chemother. 47: 1173-1173 [Full Text]  
  • Wiesner, J., Henschker, D., Hutchinson, D. B., Beck, E., Jomaa, H. (2002). In Vitro and In Vivo Synergy of Fosmidomycin, a Novel Antimalarial Drug, with Clindamycin. Antimicrob. Agents Chemother. 46: 2889-2894 [Abstract] [Full Text]  
  • Lell, B., Kremsner, P. G. (2002). Clindamycin as an Antimalarial Drug: Review of Clinical Trials. Antimicrob. Agents Chemother. 46: 2315-2320 [Full Text]  
  • (2001). A 3-Day Quinine-Clindamycin Treatment for Uncomplicated Falciparum Malaria. JWatch Infect. Diseases 2001: 8-8 [Full Text]